Rosuvastatin overdosage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Pitavastatin}} {{CMG}}; {{AE}} {{SS}} ==Overdosage== There is no specific treatment in the event of overdose. In the event of overdose, the patient should be tr...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Pitavastatin}}
{{Rosuvastatin}}
{{CMG}}; {{AE}} {{SS}}
{{CMG}}; {{AE}} {{SS}}



Revision as of 01:25, 18 February 2014

Rosuvastatin
CRESTOR® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Rosuvastatin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Overdosage

There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis does not significantly enhance clearance of rosuvastatin.[1]

References

  1. "LIVALO (PITAVASTATIN CALCIUM) TABLET, FILM COATED [KOWA PHARMACEUTICALS AMERICA, INC. ]". Retrieved 14 February 2014.

Template:Statins